Scholar Rock wins FDA approval for ISEMBYLD
Scholar Rock said the FDA approved ISEMBYLD for SMA in patients age 2 and older on an SMN2-targeted therapy, and it is starting a U.S. commercial launch.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.